Recent data suggest that inhibitors against EZH2, the enzymatic core of the PRC2 complex, which is already in advanced clinical trials in multiple tumor types including triple-negative breast cancer, mediates de-repression of the GATA3-ERα signaling axis, inducing a luminal-like phenotype that is sensitive to endocrine therapy agents such as fulvestrant46. Here, ESR1 is linked to neoplasm.